UCB Pharma Canada Announces Recipients for the Inaugural UCBeyond Crohn's Disease and Rheumatoid Arthritis Scholarship Programs

    TORONTO, Sept. 12 /CNW/ - Just in time for the new school semester,
14 exemplary Canadian students living with Crohn's disease and rheumatoid
arthritis have been awarded the first-ever UCBeyond Educational Scholarships.
    Seven (7), one-time scholarships of up to $5,000.00 CDN each have been
granted to students living with Crohn's disease and seven (7) one-time
scholarships of up to $5,000.00 CDN each have been given to students living
with rheumatoid arthritis.
    "UCB Pharma Canada thanks the hundreds of Canadian students who took the
time to complete the application process and apply for the 2007 UCBeyond
Scholarship Programs," says Rob Hamilton, General Manager of UCB Pharma
Canada. "We are proud to be announcing the winners today, and feel the
recipients perfectly personify what it means to live above and beyond their
diseases and empower others in the fight against Crohn's disease and
rheumatoid arthritis. Their stories are truly courageous and we are honoured
to assist them in achieving their dreams of pursuing a post-secondary
    The 2007 UCBeyond Scholarship recipients have been chosen by an
independent selection committee of leading physicians, nurses and patient
representatives from across Canada. Applicants were evaluated based on a
one-page essay demonstrating how they have gone above and beyond their
disease, exhibit perseverance and empower others, as well as two letters of
personal recommendation.
    "Overcoming the effects of Inflammatory Bowel Disease, rather than
letting it control you, can be an extremely difficult task. Students who have
demonstrated an ability to accomplish this exceptional feat deserve to be
recognized and rewarded and we're delighted that UCB Pharma Canada has done
just that," says Dr. Kevin Glasgow, National Executive Director of the Crohn's
and Colitis Foundation of Canada (CCFC).
    Anne Dooley, President of the Canadian Arthritis Patient Alliance (CAPA),
and a member of the rheumatoid arthritis scholarship selection committee adds,
"The UCBeyond Scholarship Program has made a big difference in the lives of
those living with rheumatoid arthritis, not only by providing assistance to
pursue educational goals, but also by motivating many to recognize how they
have gone beyond the boundaries of their disease to live successful and
fulfilling lives."
    Other proud supporters of the UCBeyond Scholarship Programs include: The
Arthritis Society (TAS), the Canadian Rheumatology Association (CRA), the
Canadian Association of Gastroenterology (CAG) and the Canadian Society of
Gastroenterology Nurses and Associates (CSGNA).

    About the scholarship recipients

    The 14 scholarship recipients were chosen from an assembly of more than
300 applications, and are nationally representative. They include:

    UCBeyond Crohn's Disease Scholarship Recipients

    1.  Joanne Baergen, Edmonton, AB - University of Alberta (Biological
    2.  Laura Bradbury, Uxbridge, ON - Ryerson University (Nursing)
    3.  Michael Goodbaum, Toronto, ON - University of British Columbia
    4.  Jessica Grossman, Toronto, ON - University of Western Ontario
    5.  Andreé-Anne Houle, Brossard, QC - Université de Sherbrooke
    6.  Michael Peplowski, Calgary, AB - University of Calgary (Biomedical
    7.  Kate Saldanha, Wolfville, NS - Acadia University
        (Psychology/Political Science)

    UCBeyond Rheumatoid Arthritis Scholarship Recipients
    1.  Rebecca Dubé, Toronto, ON - McMaster University (Biochemistry/French)
    2.  Lindsay Junkin, Peterborough, ON - Ryerson University (Culture &
    3.  Dana Landry, Winnipeg, MB - Concordia University (English)
    4.  Wyatt Loyd, Waterloo, ON - Conestoga College
    5.  Jacqueline Lukas-Bretzler, Burlington, ON - University of Toronto
    6.  Paul Morrison, Baddeck, NS - Dalhousie University (Medicine)
    7.  John Trask, Dartmouth, NS - University of Guelph (Bio Medical

    About Crohn's disease

    Crohn's disease is a chronic and debilitating inflammatory disease of the
gastrointestinal tract, affecting more than 170,000 people in Canada. The
onset of Crohn's disease often occurs between the ages of 18-25. As Crohn's
disease is a chronic ailment, people go through unpredictable periods in which
the disease flares and causes symptoms. These episodes are followed by times
of remission - periods in which symptoms disappear or decrease and good health
returns. Canada has one of the highest incidence and prevalence of Crohn's
disease in the world.

    About Rheumatoid arthritis

    Rheumatoid arthritis (RA) is a progressive autoimmune disease which
causes chronic inflammation of the joints. It is estimated that 320,000 (1 in
100) people suffer from RA in Canada.(3) Prevalence is not split evenly
between genders, since women are three times more likely to be affected than
    Although it can affect people of all ages, the onset of RA usually occurs
between 25-50 years.(5) Symptoms of RA may include joint stiffness, joint
pain, inflammation of the affected areas and an associated reduction in
mobility. These symptoms can be intermittent and vary in severity from patient
to patient. In more severe cases RA can eventually lead to disability. RA
patients are also at a higher risk of developing other conditions, in
particular heart disease, stroke, infections, lung problems and

    About UCB

    UCB (www.ucb-group.com) is a leading global biopharmaceutical company
dedicated to the research, development and commercialization of innovative
pharmaceutical and biotechnology products in the fields of central nervous
system disorders, allergy/respiratory diseases, immune and inflammatory
disorders and oncology. Employing over 8,400 people in 40 countries, UCB
focuses on securing a leading position in severe disease categories.

    About UCB Pharma Canada

    UCB Pharma Canada was officially incorporated in November, 2006 with the
objective of bringing a new-generation, convenient therapy to the Canadian
market for auto-immune, inflammatory diseases. A truly patient-focused
organization, UCB Pharma Canada's focus is bringing new and innovative
programs to patients, and the specialists who treat them, to help improve the
lives of people living with severe diseases.


    1. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the
       progression of radiologic changes in rheumatoid arthritis: Correlation
       of radiographic, clinical and laboratory abnormalities. Arthritis &
       Rheumatism , 1971, Vol. 14, No. 6.
    2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis
       Guidelines. Guidelines for the Management of Rheumatoid Arthritis 2002
       update. Arthritis & Rheumatism, 2002 Vol. 46, No. 2.
    3. http://www.arthritis.ca
    4. Panayi G What is RA? National Rheumatoid Arthritis Society, June 2006
    5. Hellier, J et al, HLA-DRB1 genes and patients with late onset
       rheumatoid arthritis, Annals of Rheumatic Disease, 2001;60:531-533
    6. Firestein G, Rheumatoid Arthritis, ACP Medicine WebMD Publishing,
       August 2004

    /NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
    the CNW Photo Network and archived at http://photos.newswire.ca.
    Additional archived images are also available on the CNW Photo Archive
    website at http://photos.newswire.ca. Images are free to accredited
    members of the media/

For further information:

For further information: on the UCBeyond Scholarship Program, or to
arrange an interview with a recipient, please contact: Chrome Communications,
(905) 567-1406; Alon Barmapov, ext. 223, (647) 405-1352,
alon@chromecommunications.ca, or Tiana DiMichele, ext. 225, (416) 666-5331,

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890